The shadow of generic challenges has long loomed around copyright’s iconic drug, Sildenafil, triggering questions about the prospects of connected drug investments. While early times saw impressive profits, the intellectual property expiration has created the door for cheaper substitutes, potentially lowering revenue and presenting a significant